Nkarta Inc. Company Profile
NASDAQ: NKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nkarta at a glance
Nkarta Inc. (NASDAQ: NKTX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in South San Francisco, CA. Nkarta is led by Mr. Paul J. Hastings and employs about 106 people. The company's shares have traded publicly since 2020.
At a market capitalization of $159.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001787400, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Nkarta do?
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Business description based on the company's public filings.
Company information
- Legal name
- Nkarta Inc.
- Ticker
- NASDAQ: NKTX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Paul J. Hastings
- Employees
- 106
- Headquarters
- 1150 Veterans Boulevard, South San Francisco, CA, United States
- Phone
- 925 407 1049
- Website
- nkartatx.com
- IPO year
- 2020
- Market cap
- $159.01M
- SEC CIK
- 0001787400
Companies similar to Nkarta
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MSLESatellos Bioscience Inc. | 7.49 | +1.97% | $158.91M | vs NKTX |
| MENSJyong Biotech Ltd. | 2.10 | 0.00% | $159.66M | vs NKTX |
| NBPNovaBridge Biosciences ADR | 1.40 | +1.82% | $161.82M | vs NKTX |
| EMISEmmis Acquisition Corp. Class A | 10.27 | 0.00% | $162.02M | vs NKTX |
| ORGOOrganogenesis Holdings Inc. Class A | 1.29 | +0.78% | $165.99M | vs NKTX |
| ANTXAN2 Therapeutics Inc. | 4.40 | -5.98% | $166.04M | vs NKTX |
| NERVMinerva Neurosciences Inc | 3.18 | -1.24% | $151.84M | vs NKTX |
| TLSATiziana Life Sciences Ltd. | 1.19 | +5.31% | $151.44M | vs NKTX |